CytomX Therapeutics, Inc.
CTMX
Positions held
Your positionsCTMX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $538.21M | Enterprise value | $213.64M | Trailing P/E | — | Forward P/E | -5.22 |
| PEG | — | Price / book | 1.78 | Beta | 2.20 | Dividend yield | 0.00% |
| Revenue growth | -92.4% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -16.8% |
| Profit margin | 0.0% | ROE | -37.8% | ROA | -19.6% | Debt / equity | 0.02 |
| Current ratio | 9.36 | Free cash flow | -$75.21M | Analyst recommendation | strong_buy | Mean target | $12.25 |
| 52w high | $8.21 | 52w low | $2.43 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $10.3M | $0.7M | $6.0M | $18.7M | — |
| Op margin | -1677.1% | -191.8% | -4213.0% | -264.4% | -6.9% | — |
| Net income | -$20.7M | -$18.2M | -$26.5M | -$14.2M | -$0.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$23.8M | -$19.7M | -$27.9M | -$15.8M | -$1.3M | — |
- Revenue -86% vs prior quarter ($1.4M vs $10M).
- Operating margin compressed to -1677.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $76.2M | $138M | $101M | $53.2M |
| Op margin | -29.3% | 18.1% | -6.4% | -190.6% |
| Net income | -$17.4M | $31.9M | -$0.6M | -$99.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · CytomX Therapeutics to Present at Upcoming September Investor Conferences
2026-08-27 · CytomX's Varseta-M Receives FDA Fast-Track Designation to Treat Colorectal Cancer
2026-08-07 · CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
2026-08-07 · CytomX Therapeutics Q2 Earnings Call Highlights
2026-08-06 · CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-06 · CytomX Therapeutics: Q2 Earnings Snapshot
2026-08-06 · CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
2026-08-06 · CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
2026-08-03 · CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
2026-07-30 · CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-27 · CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
Price (daily)
Full chart · RSI · MACD · patterns